CCXI News Alert Chemocentryx Inc (CCXI) 6.64 12/25/2014 11:4

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Chemocentryx Inc (CCXI) 6.64 $CCXI

Biotech Stock Roundup: Sophiris & Cyclacel Plunge on Data, ChemoCentryx Gains on Positive Results - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 17, 9:26AM CST
It has been a relatively quiet week with the holiday season coming up though a few companies came out with important pipeline updates.
CYCC: 0.69 (+0.01), CBST: 100.29 (-0.09), SPHS: 0.46 (+0.02), CCXI: 6.64 (-0.04), ALXN: 181.96 (+3.09), EXEL: 1.29 (-0.01)

ChemoCentryx Up on Positive Diabetic Nephropathy Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 5:45PM CST
ChemoCentryx, Inc., announced positive top-line 52-week data from its phase II study on its candidate CCX140 for diabetic nephropathy.
ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), SCMP: 13.75 (+0.44), CCXI: 6.64 (-0.04)

Can The Uptrend Continue for ChemoCentryx (CCXI)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 10:22AM CST
Can The Uptrend Continue for ChemoCentryx (CCXI)?
CCXI: 6.64 (-0.04)

ChemoCentryx (CCXI) Shows Strength: Stock Moves Up 24.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 7:51AM CST
ChemoCentryx, Inc. (CCXI) was a big mover last session, as its shares rose almost 25% on the day.
LCI: 42.29 (+1.79), SCMP: 13.75 (+0.44), CCXI: 6.64 (-0.04), IG: 9.11 (-0.01)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 4:39PM CST

ENPH: 14.38 (-0.02), ATTO: 9.94 (-0.16), TVIX: 2.29 (-0.02), GGB: 3.56 (-0.08), ARRS: 30.17 (+0.30), DGAZ: 7.23 (+0.74), SGMO: 14.20 (+0.14), CCXI: 6.64 (-0.04), ILF: 31.85 (+0.05), GSAT: 2.97 (+0.03)

Why ChemoCentryx Inc's Shares Shot 60% Higher Today
Alex Planes, The Motley Fool - Motley Fool - Fri Dec 12, 12:02PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ChemoCentryx have gained more than 60% as...
CCXI: 6.64 (-0.04)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 11:46AM CST

ESL: 111.32 (+1.61), CGA: 1.54 (-0.06), FRO: 2.43 (-0.01), RTK: 1.26 (-0.01), TLM: 7.84 (unch), MILL: 1.23 (-0.07), ZQK: 2.43 (-0.06), EOX: 1.33 (+0.05), HGSH: 4.60 (-0.06), ISIG: 3.78 (+0.02), DRL: 3.38 (-0.02), EROC: 2.25 (+0.10), SSTK: 67.78 (+0.04), CISG: 6.29 (+0.04), SOFO: 7.48 (-0.11), CELP: 14.50 (-0.14), CCXI: 6.64 (-0.04), MPO: 1.63 (-0.05), NAO: 13.13 (-0.38), VNR: 16.87 (-0.19)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 8:16AM CST

FRO: 2.43 (-0.01), GDP: 4.93 (-0.22), TLM: 7.84 (unch), ONVO: 6.84 (+0.03), EOX: 1.33 (+0.05), CCXI: 6.64 (-0.04), HCCI: 11.76 (-0.41), ONTY: 1.89 (+0.01), ADBE: 74.74 (+0.36)

ChemoCentryx soars on Phase 2 results
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 7:56AM CST

CCXI: 6.64 (-0.04)

ChemoCentryx Announces Positive Results in Phase II Diabetic Nephropathy Trial With CCR2 Inhibitor CCX140
GlobeNewswire - Fri Dec 12, 5:30AM CST
Primary Endpoint Achieved; Statistically Significant Reduction in Urinary Protein Over 52 Weeks
CCXI: 6.64 (-0.04)

Fatty Liver Disease - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/7dx4sz/fatty_liver) has announced the addition of the "Fatty Liver Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fatty Liver Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fatty Liver Disease and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fatty Liver Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Fatty Liver Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - GW Pharmaceuticals plc - Protalix BioTherapeutics, Inc. - Genovate Biotechnology Co., LTD. - Huons Co., Ltd. - ChemoCentryx, Inc. - ACROVIS biostructures GmbH - Generon (Shanghai) Corporation Ltd. For more information visit http://www.researchandmarkets.com/research/7d...atty_liver
CCXI: 6.64 (-0.04)

ChemoCentryx to Host Conference Call on Friday, December 12, 2014 to Discuss Top-Line Phase II Results in Patients With Diabetic Nephropathy With CCX140, an Orally Administered CCR2 Inhibitor
GlobeNewswire - Thu Dec 11, 3:30PM CST
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today announced that it will host a conference call and webcast on Friday, December 12, 2014 at 8:30 a.m. Eastern Time (ET) to present top-line results from its Phase II trial with CCX140, an inhibitor of the chemokine receptor known as CCR2, in patients with diabetic nephropathy.
CCXI: 6.64 (-0.04)

ChemoCentryx: Can It Break Into The Soliris Market?
Kanak Kanti De - at Seeking Alpha - Thu Dec 11, 2:08PM CST

ALXN: 181.96 (+3.09), CCXI: 6.64 (-0.04)

ChemoCentryx (CCXI) Shows Strength: Stock Moves Up 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 8:39AM CST
ChemoCentryx, Inc. (CCXI) was a big mover last session, as its shares rose almost 6% on the day.
LCI: 42.29 (+1.79), SCMP: 13.75 (+0.44), CCXI: 6.64 (-0.04), IG: 9.11 (-0.01)

ChemoCentryx Drug Gets Orphan Designation in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 5:07PM CST
Positive news flowed in for ChemoCentryx, Inc., (CCXI) when it announced that the European Commission has granted orphan medicinal product designation to its pipeline candidate CCX168.
VRX: 140.33 (-0.22), ARQL: 1.15 (+0.01), SCMP: 13.75 (+0.44), CCXI: 6.64 (-0.04)

ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
GlobeNewswire - Thu Dec 04, 7:30AM CST
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, reported today that the European Commission has granted orphan medicinal product designation for CCX168, an orally administered inhibitor targeting the receptor for the complement protein known as C5a (C5aR), for the treatment of microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) (formerly known as Wegener's Granulomatosis, or WG). Both conditions are forms of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV).
CCXI: 6.64 (-0.04)

Atherosclerosis - Pipeline Review, H2 2014
M2 - Tue Dec 02, 6:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/xjlf7c/atherosclerosis) has announced the addition of the "Atherosclerosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Atherosclerosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to ehance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aastrom Biosciences, Inc. - Ache Laboratorios Farmaceuticos S/A - advanceCor GmbH - AFFiRiS AG - Arisaph Pharmaceuticals, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Athera Biotechnologies AB - AtheroNova Inc. - AuraSense Therapeutics, LLC - Bayer AG - Boehringer Ingelheim GmbH - Bridge Bioresearch Plc - Bristol-Myers Squibb Company - Cardax Pharmaceuticals, Inc. - ChemoCentryx, Inc. - CIMAB S.A. - CSL Limited - DoNatur GmbH - Dr. Reddy's Laboratories Limited - Dybly AG - GlaxoSmithKline plc - Isis Pharmaceuticals, Inc. - Johnson & Johnson - KineMed, Inc. - Kowa Company, Ltd. - Lead Discovery Center GmbH - MedImmune, LLC - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/xj...osclerosis
KNMD: (), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), JNJ: 104.59 (+0.31), ISIS: 59.49 (+1.88), AZN: 70.44 (+0.26), CCXI: 6.64 (-0.04)

ChemoCentryx aHUS drug candidate an Orphan Drug
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 3:52PM CST

CCXI: 6.64 (-0.04)

ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in Atypical Hemolytic Uremic Syndrome Treatment by the FDA
GlobeNewswire - Thu Nov 20, 3:30PM CST
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, reported today that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for CCX168, an orally administered inhibitor targeting the receptor for the complement protein known as C5a (C5aR). The designation is for the treatment of atypical Hemolytic Uremic Syndrome (aHUS). Atypical hemolytic uremic syndrome is a rare, life-threatening, progressive disease, frequently with a genetic component, that primarily affects kidney function.
CCXI: 6.64 (-0.04)

ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit in Non-Renal ANCA Vasculitis Disease Activity, in Addition to Previously Shown Kidney Disease Improvements
GlobeNewswire - Mon Nov 17, 7:42AM CST
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today reported additional data from a Phase II clinical trial (the CLEAR trial) with CCX168, an inhibitor targeting the receptor for the complement protein known as C5a (C5aR), in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Dr. David Jayne from Addenbrooke's Hospital in Cambridge, UK, Principal Investigator of the study, delivered an oral presentation at the American College of Rheumatology (ACR) Annual Meeting in Boston, MA, taking place from November 14-19, 2014.
CCXI: 6.64 (-0.04)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 108

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
U.S. Employers Signal a Deeper Multilingual Skills Gap

Updated Category News Views 101

A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...

Continue Reading
AlphaPoint's Approval Device Targets AI Attack Risk

Updated Category News Views 45

A Separate Screen May Be Worth More Than Another Patch AlphaPoint is taking a fairly old security instinct and aiming it at a very current headache: if the laptop is lying to the employee, do not let the laptop have the final say. Its newly introduced Approval Device is dedicated hardware with its own display, built to let authorized staff inspect and approve sensitive...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 103

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
Water Damage Coverage Has More Traps Than Homeowners Think

Updated Category News Views 29

A wet basement does not care one bit whether the water arrived dramatically or dripped in for months. That ugly distinction, though, can decide whether a homeowner has an insurance claim or a repair bill that lands with a thud. Kathy Thurmond-Edwards, an insurance expert in Memphis, Tennessee, lays out the dividing lines plainly: sudden pipe failures may be treated very...

Continue Reading
Birkenstock’s Athens Stores Put Brand Control to Work

Updated Category News Views 76

A 62-square-meter shop on Ermou Street can say plenty about a brand’s ambitions. Birkenstock is opening its first two Greek stores in Athens, moving beyond its existing wholesale and retail-partner presence with locations it can shape from the floorboards up. The first site at Ermou 18 is stated to have opened on November 12, 2026; the announcement itself is dated...

Continue Reading
Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 118

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 99

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 73

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 62

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading

Top 5 Most Recently Viewed Articles

Redsun Properties Faces $350 Million Bond Payment Crisis Ahead

Updated Category News Views 189

Redsun Properties Announces Inability to Pay Bond Chinese property developer Redsun Properties has communicated its inability to meet a $350 million bond payment, which is due shortly. This situation has raised considerable concern within the financial markets as it highlights the ongoing issues facing property developers in China. Details of the Bond Issue This bond,...

Continue Reading
Etruscus Resources Unveils Promising Findings at Zappa Target

Updated Category News Views 135

Etruscus Resources Makes Progress at Key Exploration Sites Etruscus Resources Corp. is thrilled to report on the encouraging findings from its exploration program at the Rock & Roll Property. This property is situated in the Golden Triangle region, known for its wealth of mineral resources. The exploration program, which included comprehensive rock sampling and geological...

Continue Reading
MetLife's Strategic Focus: Navigating Q3 2024 Earnings

Updated Category News Views 1091

MetLife Announces Q3 2024 Results and New Frontier Strategy In the third quarter of 2024, MetLife, Inc. (MET) reported adjusted earnings of $1.4 billion, translating to $1.93 per share. This reflects a decline from previous year figures, yet a 12% year-to-date increase in adjusted earnings per share (EPS) excluding notable items. The insurance powerhouse has seen positive...

Continue Reading
VEON Invests in Ukraine: Commitment to Digital Growth

Updated Category News Views 125

VEON's Commitment to Investing in Ukraine VEON Ltd. (NASDAQ: VEON), a leading global digital operator, has recently made significant news with its promise to enhance Ukraine’s telecommunications infrastructure. In collaboration with its fully-owned subsidiary, Kyivstar, VEON participated in the 2024 Yalta European Strategy (YES) Annual Meeting. At this event, the focus...

Continue Reading
Expanding Diabetes Care: From Monitoring to Change

Updated Category News Views 44

Breaking Ground at the AGP & DTx Summit Diabetes management ain't what it used to be, and the 4th AGP & DTx Summit in Shenzhen gave us an eyeful of change. Under the banner "Beyond Glucose," experts from all corners came together to talk shop about Continuous Glucose Monitoring (CGM) and how it might shake up diabetes care. CGM: More Than a Gadget See, CGM's not just a...

Continue Reading